PARIS (dpa-AFX) - Sanofi Pasteur's (SNYNF, SNY ) first Phase III trial with dengue vaccine candidate met its primary clinical endpoint, showing a significant decrease in 56 percent of dengue disease cases. It was also found to have good safety profile.
Commenting on the results, Sanofi's Chief executive said : 'Developing a dengue vaccine for the benefit of children and their parents is at the heart of our mission. Our goal is to make dengue the next vaccine-preventable disease and to support the WHO's ambition to reduce dengue mortality by 50% and morbidity by 25% by 2020.'
The company announced that the results of this first, large-scale efficacy study will be further complemented by results in the third-quarter of 2014, from a second, large-scale study currently conducted in Latin America, involving more than 20,000 volunteers from Brazil, Colombia, Honduras, Mexico and Puerto Rico.
Copyright RTT News/dpa-AFX